Boston-based biopharma Rapport Therapeutics, backed by Johnson & Johnson's VC, files for US IPO on Nasdaq under "RAPP" to raise capital for CNS disorder medicines.
Rapport Therapeutics, a Boston-based biopharmaceutical company backed by Johnson & Johnson's venture capital, filed for an IPO in the US to develop small-molecule medicines for central nervous system disorders. The firm plans to list on the Nasdaq under "RAPP" and aims to raise capital for operations. Goldman Sachs, Jefferies, TD Cowen, and Stifel are the underwriters for the offering.
May 17, 2024
3 Articles